Abbott Laboratories

111.50-0.3200-0.29%Vol 1.58M1Y Perf -14.01%
Feb 2nd, 2023 11:32 DELAYED
BID111.49 ASK111.50
Open111.28 Previous Close111.82
Pre-Market111.02 After-Market-
 -0.80 -0.72%  - -
Target Price
118.53 
Analyst Rating
Strong Buy 1.41
Potential %
6.29 
Finscreener Ranking
★★+     47.62
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.51
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     57.38
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★     46.54
Price Range Ratio 52W %
48.43 
Earnings Rating
Neutral
Market Cap194.41B 
Earnings Date
25th Jan 2023
Alpha0.01 Standard Deviation0.06
Beta0.75 

Today's Price Range

110.89111.94

52W Range

93.25130.94

5 Year PE Ratio Range

29.90277.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.68%
1 Month
1.85%
3 Months
14.06%
6 Months
2.93%
1 Year
-14.01%
3 Years
28.32%
5 Years
81.26%
10 Years
248.88%

TickerPriceChg.Chg.%
ABT111.50-0.3200-0.29
AAPL150.174.74003.26
GOOG108.156.72006.63
MSFT261.939.17733.63
XOM112.09-2.6500-2.31
WFC47.280.25000.53
JNJ163.98-0.9400-0.57
FB196.640.99000.51
GE82.680.36000.44
JPM139.750.16000.11
 
ProfitabilityValueIndustryS&P 500US Markets
57.10
21.90
29.30
14.60
17.58
RevenueValueIndustryS&P 500US Markets
33.56B
19.25
11.63
11.85
DividendsValueIndustryS&P 500US Markets
1.82
2.04
14.58
11.63
Payout ratio45.00
Earnings HistoryEstimateReportedSurprise %
Q04 20220.901.0314.44
Q03 20220.901.1527.78
Q02 20221.091.4331.19
Q01 20221.471.7317.69
Q04 20211.181.3211.86
Q03 20210.921.4052.17
Q02 20211.011.1715.84
Q01 20211.331.32-0.75
Earnings Per EndEstimateRevision %Trend
12/2022 QR0.90-5.26Negative
12/2022 FY5.214.41Positive
3/2023 QR1.00-8.26Negative
12/2023 FY4.39-5.18Negative
Next Report Date-
Estimated EPS Next Report0.90
Estimates Count9
EPS Growth Next 5 Years %5.10
Volume Overview
Volume1.58M
Shares Outstanding1.74M
Shares Float1.71B
Trades Count17.94K
Dollar Volume176.24M
Avg. Volume4.76M
Avg. Weekly Volume4.59M
Avg. Monthly Volume5.00M
Avg. Quarterly Volume4.69M

Abbott Laboratories (NYSE: ABT) stock closed at 111.82 per share at the end of the most recent trading day (a 1.15% change compared to the prior day closing price) with a volume of 4.51M shares and market capitalization of 194.41B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.

The one-year performance of Abbott Laboratories stock is -14.01%, while year-to-date (YTD) performance is 1.85%. ABT stock has a five-year performance of 81.26%. Its 52-week range is between 93.25 and 130.935, which gives ABT stock a 52-week price range ratio of 48.43%

Abbott Laboratories currently has a PE ratio of 25.40, a price-to-book (PB) ratio of 5.49, a price-to-sale (PS) ratio of 5.83, a price to cashflow ratio of 19.30, a PEG ratio of 2.32, a ROA of 11.66%, a ROC of 15.73% and a ROE of 24.34%. The company’s profit margin is 17.58%, its EBITDA margin is 29.30%, and its revenue ttm is $33.56 Billion , which makes it $19.25 revenue per share.

Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.90 for the next earnings report. Abbott Laboratories’s next earnings report date is -.

The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.41), with a target price of $118.53, which is +6.29% compared to the current price. The earnings rating for Abbott Laboratories stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abbott Laboratories has a dividend yield of 1.82% with a dividend per share of $2.04 and a payout ratio of 45.00%.

Abbott Laboratories has a Buy technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 2.01, CCI20 : -45.17, Chaikin Money Flow : 0.01, MACD : 0.54, Money Flow Index : 37.56, ROC : -1.49, RSI : 54.28, STOCH (14,3) : 50.60, STOCH RSI : 0.78, UO : 52.64, Williams %R : -49.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Sold 456 shares of value $53 866 ), Christopher J. Calamari (Sold 706 shares of value $83 414 ), Daniel Gesua Sive Salvadori (Sold 1 550 shares of value $183 165 ), Daniel J. Starks (Sold 150 000 shares of value $15 990 972 ), Fernando Mateus (Sold 2 457 shares of value $267 943 ), Gregory A. Ahlberg (Sold 1 099 shares of value $129 847 ), Hubert L. Allen (Sold 1 450 shares of value $171 348 ), Jared L. Watkin (Sold 1 038 shares of value $122 589 ), John F. Ginascol (Sold 11 000 shares of value $1 235 520 ), Joseph J. Manning (Option Excercise at a value of $2 043 110), Joseph J. Manning (Sold 50 685 shares of value $5 378 990 ), Julie L. Tyler (Sold 715 shares of value $82 714 ), Lisa D. Earnhardt (Sold 943 shares of value $111 416 ), Louis H. Morrone (Sold 656 shares of value $77 513 ), Michael D. Dale (Sold 5 053 shares of value $592 413 ), Nancy Mckinstry (Option Excercise at a value of $187 394), Nancy Mckinstry (Sold 1 614 shares of value $187 910 ), Randel W. Woodgrift (Option Excercise at a value of $1 065 600), Randel W. Woodgrift (Sold 24 964 shares of value $2 825 952 ), Robert B. Ford (Option Excercise at a value of $4 121 870), Robert B. Ford (Sold 102 425 shares of value $10 765 154 ), Sammy Karam (Sold 4 200 shares of value $456 750 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
12 (75.00 %)
12 (75.00 %)
Moderate Buy
3 (18.75 %)
2 (12.50 %)
2 (12.50 %)
Hold
2 (12.50 %)
2 (12.50 %)
2 (12.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.41
Strong Buy
1.38
Strong Buy
1.38

Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

CEO: Robert B. Ford

Telephone: +1 224 667-6100

Address: 100 Abbott Park Road, Abbott Park 60064-6400, IL, US

Number of employees: 109 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

63%38%

Bearish Bullish

53%47%

Bearish Bullish

58%42%

TipRanks News for ABT

Sat, 28 Jan 2023 01:45 GMT Abbott Labs (ABT) Gets a Buy from RBC Capital

- TipRanks. All rights reserved.

Fri, 21 Oct 2022 12:36 GMT Abbott Labs (ABT) Gets a Buy from Raymond James

- TipRanks. All rights reserved.

Wed, 27 Jul 2022 16:49 GMT Abbott Labs (ABT) Receives a Buy from UBS

- TipRanks. All rights reserved.

Wed, 20 Jul 2022 15:27 GMT Abbott Posts Q2 Beat & Raises EPS Guidance

- TipRanks. All rights reserved.

Fri, 15 Jul 2022 12:40 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and HCA Healthcare (HCA)

- TipRanks. All rights reserved.

Thu, 14 Jul 2022 12:15 GMT Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), CytomX Therapeutics (CTMX)

- TipRanks. All rights reserved.

Mon, 11 Jul 2022 13:58 GMT Abbotts Sturgis Facility Restarts Operations

- TipRanks. All rights reserved.

News

Stocktwits